New York, April 09, 2024 - PRISM MarketView - PRISM Cannabis Index laggard, Tilray Brands (TLRY) announced disappointing Q3 earnings that missed on Q3 EPS ($0.12) vs Factset ($0.05) as well as quarterly revenues $188.3M vs Factset $198.3M. Furthermore, the company cited due to delayed timing of cash collection on various asset sales, the generation of positive adjusted free cash flow for the full FY24, is no longer expected.
Some highlights from the company Q&A that were discussed included opportunity in Germany as laws have changed, impacts to market share occurred from operational complexities due to SKU relocations and expect to recover once this process is complete, a Canadian excise tax change could positively impact Tilray and savings would be reinvested into the business, and if the US reschedules medical cannabis, Tilray intends to utilize its expertise to rapidly expand into the market.
While its Q3 earnings were dismal, as legislation evolves there may be opportunity for Tilray to turn things around if it can successfully execute.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)